Abstract

In recent years, a substantial number of new randomized clinical trials have been conducted in the field of valvular heart disease. In light of these developments, and with the aim of updating clinical practice, the 2025 European Society of Cardiology (ESC) guidelines for the management of valvular heart disease have been revised. The updated guideline places a stronger emphasis on technological advancements in minimally invasive interventions and their long-term outcomes; the expanded application of advanced diagnostic imaging modalities; a more precise definition of the management of multivalvular disease and concomitant coronary lesions; as well as the importance of individualized patient-centered decision-making, the multidisciplinary “heart team” approach, and center expertise. The overarching objective of this revision is to bridge the gap between scientific evidence and clinical implementation, thereby promoting greater precision and consistency in the timing and selection of therapeutic interventions. In this review, we aim to analyze and interpret the novel and updated recommendations presented in the 2025 ESC guidelines for valvular heart disease, and to provide a concise summary of the most current evidence to inform clinical practice.